Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_4
2
67%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 42 (66.7%)

Trials by Status

completed267%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnphase_1

Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL

NCT03398252
completedphase_4

Alpha-Blockers in Allergic Rhinitis (MAN 01)

NCT01946035
completedphase_4

A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

NCT01959022

Clinical Trials (3)

Showing 3 of 3 trials
NCT03398252Phase 1

Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL

Withdrawn
NCT01946035Phase 4

Alpha-Blockers in Allergic Rhinitis (MAN 01)

Completed
NCT01959022Phase 4

A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3